Investment Overview - Novartis Latest M&A Deal Speaks to Pipeline Pressure A few days ago (March 20th), Swiss Pharmaceuticals giant Novartis (NVS) announced it would pay $2bn up front (the deal may rise to $3bn if milestones are met) to acquire Pikavation Therapeutics, a wholly owned subsidiary of Synnovation, a privately owned Biotech headquartered in Delaware. The clue is in the name - Pikavation is developing SNV4818, a pan-mutant‑selective PI3Kα inhibitor, "exploring a next-generation approach for the t ...

Fennec Pharmaceuticals Inc. (NASDAQ:FENC) will release earnings results for its fourth quarter, before the opening bell on Tuesday, March 24.Analysts expect the Research Triangle Park, North Carolina-based company to report quarterly earnings at 4 cents per share, versus a year-ago loss of 6 cents per share. The consensus estimate for Core & Main's quarterly revenue is $14.73 million, versus $7.92 million a year earlier, according to data from Benzinga Pro.On March 16, Fennec Pharmaceuticals announced a set ...

And right now we are 2 minutes away from the end of the trading day. Romaine Bostick here with Katie Greifeld taking you through to that closing bell. It's a global simulcast.Carol Massar Tim back there joining us now. Welcome to our audiences across all of our Bloomberg platforms, television, radio, our partnership with YouTube. Another wild day Carol Massar on Wall Street.But it actually started before the cash session back in the futures market in the wee hours of around 7 a. m. I know you're probably st ...

NEW YORK, March 23, 2026 (GLOBE NEWSWIRE) -- Shareholder rights firm Levi & Korsinsky, LLP is representing investors in Inovio Pharmaceuticals, Inc. (NASDAQ: INO) who purchased securities during the Class Period. THE INVESTIGATION: The action alleges that Inovio and certain officers made false or misleading statements during the period from October 10, 2023 through December 26, 2025. The Efficient Market Hypothesis Securities class actions often rely on the efficient market hypothesis — the theory that in a ...

NEW YORK, March 23, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Corcept Therapeutics Incorporated ("Corcept Therapeutics Incorporated" or the "Company") (NASDAQ: CORT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Corcept Therapeutics Incorporated investors who were adversely affected by alleged securities fraud between October 31, 2024 and December 30, 2025. Follow the link below to get more information and be contacted by ...

Did you buy SLNO common stock between March 26, 2025, and November 4, 2025? Affected Soleno Therapeutics, Inc. Investor Summary Who: Soleno Therapeutics, Inc. (NASDAQ: SLNO)What: Securities fraud class action lawsuit filedClass Period: March 26, 2025, through November 4, 2025Deadline to Seek Lead Plaintiff Status: May 5, 2026Key Lawsuit Allegations: Material misstatements and/or omissions concerning the company’s Phase 3 clinical trial program for diazoxide choline extended-release tablets (“DCCR”).Investor ...

New York, New York--(Newsfile Corp. - March 23, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allegations that Disc Medicine may have issued materially misleading business information to the investing public.SO WHAT: If you purchased Disc Medicine securities you may be entitled to compensation without payment of any out of pocket fees or costs through a ...

In this article, we will discuss Jim Cramer Stock Portfolio: Top 10 Stock Picks.Markets rebounded sharply on Monday after President Donald Trump announced a pause in strikes against Iran and said the US was engaged in talks with Tehran. Just hours earlier, investor sentiment was extremely negative as markets awaited the end of Trump’s 48-hour deadline for Iran to reopen the Strait of Hormuz or face “obliteration” of its power plants.Jim Cramer, during his Friday’s program on CNBC, had told investors that th ...

Bausch + Lomb (NYSE:BLCO) Update / briefing March 23, 2026 01:30 PM ET Company ParticipantsBrent Saunders - Chairman and CEOCathleen McCabe - Strategic Medical AdvisorKelly Swaim - SVP of Surgical R&DMayssa Attar - SVP of Pharmaceuticals and Consumer R&DYehia Hashad - EVP of R&D and Chief Medical OfficerConference Call ParticipantsLarry Biegelsen - Medical Device AnalystLarry BiegelsenGood afternoon. I'm Larry Biegelsen, the medical device analyst at Wells Fargo. Welcome to the next call in our 2026 MedTech ...

AbbVie (ABBV 0.21%) is a top healthcare stock, but it isn't trading like one of late. This year, it's down 11%, and it has been underperforming the S&P 500, which is down only 4%. Investors have been bearish on healthcare stocks as a whole, with the Healthcare Select Sector SPDR ETF falling by 6% thus far. Concerns about healthcare reform and government cuts have been weighing on the sector.For investors, however, now can be an opportune time to buy low on a quality stock such as AbbVie. While it may not be ...